SEOUL, May 21 (Korea Bizwire) — SK bioscience Co., a biotech arm of South Korea’s SK Group, said Wednesday it has won a patent lawsuit against global pharmaceutical giant Pfizer Inc. over pneumococcal vaccine components. In 2020, Pfizer filed a lawsuit with a Korean court, claiming that SK bioscience’s export of 13-valent pneumococcal conjugate vaccine [...]
SEOUL, May 21 (Korea Bizwire) — The U.S. Food and Drug Administration (FDA) is currently conducting an on-site inspection of Samsung Biologics Co.’s production facilities in South Korea, industry sources said Wednesday. According to the sources, the FDA launched the inspection at the company’s facilities in Songdo, west of Seoul, and is scheduled to continue [...]
INCHEON, May 17 (Korea Bizwire) — South Korea has begun construction on a state-funded facility dedicated to advancing animal-free toxicity testing methods, a move that signals the country’s commitment to ethical science, chemical safety, and animal welfare. The Ministry of Environment held a groundbreaking ceremony Thursday at the Korea Environment Corporation headquarters in Seo-gu, Incheon, to [...]
SEOUL, May 15 (Korea Bizwire) – The government held a consultative meeting with private sector stakeholders Thursday to promote the use of artificial intelligence (AI) in drug development in response to the intensifying global competition in the bio-health sector. The meeting brought together officials from the Ministry of Economy and Finance and other relevant government [...]
SEOUL, May 15 (Korea Bizwire) — Celltrion Inc., a leading South Korean biopharmaceutical company, said Thursday its business will remain largely unaffected by U.S. President Donald Trump’s executive order aimed at lowering drug prices to match those in other countries. The order seeks to address a drug pricing system in which the United States pays [...]
SEOUL, May 14 (Korea Bizwire) — South Korea’s pharmaceutical and biotech companies view the Trump administration’s push to lower U.S. prescription drug prices as a potential tailwind for domestic drugmakers, particularly those in the biosimilar space. Former President Donald Trump, who is expected to run again in the 2026 election, issued an executive order last week [...]
SEOUL, May 7 (Korea Bizwire) — The Korea Biotechnology Industry Organization (KBIO) said Wednesday it has requested the United States to exempt South Korea from the Donald Trump administration’s plan to impose tariffs on pharmaceutical imports. KBIO said it submitted such an opinion formally to the U.S. Department of Commerce on Tuesday (U.S. time) regarding [...]
SEOUL, May 6 (Korea Bizwire) — South Korea’s retail sector is undergoing a transformation, with department stores, convenience chains, e-commerce platforms, and home shopping networks all doubling down on health supplements as a key growth driver in the post-pandemic era. Spurred by the rise of the “Healthy Pleasure” lifestyle — where consumers actively enjoy health management [...]
SEOUL, May 5 (Korea Bizwire) — As global competition heats up in the pharmaceutical and biotech sectors, major players in South Korea and abroad are accelerating efforts to expand the therapeutic indications of existing drugs—a strategy aimed at maximizing product value and securing wider market share. According to industry sources on May 4, Korea Novo Nordisk [...]
SEOUL, April 25, (Korea Bizwire) — South Korea’s biohealth industry is projected to grow at an annual rate of nearly 9 percent, reaching $370.3 billion by 2030 and ranking eighth globally, according to a new market outlook released by the Korea Health Industry Development Institute (KHIDI) on April 25. The report, titled 2025 Global Biohealth [...]